Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts

José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, Juan Betuel Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar

Article Type

Review

Published

Heart failure (HF) represents a major healthcare problem, reaching epidemic figures worldwide. This article provides an update on the vulnerable period of HF with reduced ejection fraction (HFrEF) and recommendations are given regarding the management of HF during this phase.

Read more

Diuretic resistance and the role of albumin in congestive heart failure

Carol Fernandez Hazim, Gustavo Duarte, Ana P Urena, Swati Jain, Rishabh Mishra, Timothy J Vittorio, Miguel Rodriguez-Guerra

Article Type

Review

Published

This review aims to expose the multiple approaches for treatment of patients with diuretic resistance and the importance of intravascular volume expansion in the response to therapy.

Read more

Optimization of GDMT for patients with heart failure and reduced ejection fraction: can physiological and biological barriers explain the gaps in adherence to heart failure guidelines?

Marilyne Jarjour, Anique Ducharme

Article Type

Review

Published

The authors provide a comprehensive overview of clinicians’ adherence to heart failure guidelines in a specialized real-life setting, particularly regarding use and optimization of guideline-derived medical therapies, as well as the implementation of more recent agents. They seek potential explanations for suboptimal treatment and its impact on patient outcomes.

Read more

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

Article Type

Review

Published

This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.